Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD - PubMed (original) (raw)
Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD
Annette Künkele et al. Cancer Immunol Res. 2015 Apr.
Abstract
Chimeric antigen receptor (CAR) development is biased toward selecting constructs that elicit the highest magnitude of T-cell functional outputs. Here, we show that components of CAR extracellular spacer and cytoplasmic signaling domain modulate, in a cooperative manner, the magnitude of CD8(+)CTL activation for tumor-cell cytolysis and cytokine secretion. Unexpectedly, CAR constructs that generate the highest in vitro activity, either by extracellular spacer length tuning or by the addition of cytoplasmic signaling modules, exhibit attenuated antitumor potency in vivo, whereas CARs tuned for moderate signaling outputs mediate tumor eradication. Recursive CAR triggering renders CTLs expressing hyperactive CARs highly susceptible to activation-induced cell death (AICD) as a result of augmented FasL expression. CAR tuning using combinations of extracellular spacers and cytoplasmic signaling modules, which limit AICD of CD8(+)CTLs, may be a critical parameter for achieving clinical activity against solid tumors.
©2015 American Association for Cancer Research.
Similar articles
- The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.
Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, Jensen MC, Riddell SR. Hudecek M, et al. Cancer Immunol Res. 2015 Feb;3(2):125-35. doi: 10.1158/2326-6066.CIR-14-0127. Epub 2014 Sep 11. Cancer Immunol Res. 2015. PMID: 25212991 Free PMC article. - Peptide modification or blocking of CD8, resulting in weak TCR signaling, can activate CTL for Fas- but not perforin-dependent cytotoxicity or cytokine production.
Kessler B, Hudrisier D, Schroeter M, Tschopp J, Cerottini JC, Luescher IF. Kessler B, et al. J Immunol. 1998 Dec 15;161(12):6939-46. J Immunol. 1998. PMID: 9862728 - Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells.
Frigault MJ, Lee J, Basil MC, Carpenito C, Motohashi S, Scholler J, Kawalekar OU, Guedan S, McGettigan SE, Posey AD Jr, Ang S, Cooper LJ, Platt JM, Johnson FB, Paulos CM, Zhao Y, Kalos M, Milone MC, June CH. Frigault MJ, et al. Cancer Immunol Res. 2015 Apr;3(4):356-67. doi: 10.1158/2326-6066.CIR-14-0186. Epub 2015 Jan 19. Cancer Immunol Res. 2015. PMID: 25600436 Free PMC article. - CD158 receptor controls cytotoxic T-lymphocyte susceptibility to tumor-mediated activation-induced cell death by interfering with Fas signaling.
Gati A, Guerra N, Gaudin C, Da Rocha S, Escudier B, Lécluse Y, Bettaieb A, Chouaib S, Caignard A. Gati A, et al. Cancer Res. 2003 Nov 1;63(21):7475-82. Cancer Res. 2003. PMID: 14612548 - NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma.
Xu X, Huang W, Heczey A, Liu D, Guo L, Wood M, Jin J, Courtney AN, Liu B, Di Pierro EJ, Hicks J, Barragan GA, Ngai H, Chen Y, Savoldo B, Dotti G, Metelitsa LS. Xu X, et al. Clin Cancer Res. 2019 Dec 1;25(23):7126-7138. doi: 10.1158/1078-0432.CCR-19-0421. Epub 2019 Sep 4. Clin Cancer Res. 2019. PMID: 31484667 Free PMC article.
Cited by
- Exploring the potential of the convergence between extracellular vesicles and CAR technology as a novel immunotherapy approach.
Bar O, Porgador A, Cooks T. Bar O, et al. J Extracell Biol. 2024 Sep 26;3(9):e70011. doi: 10.1002/jex2.70011. eCollection 2024 Sep. J Extracell Biol. 2024. PMID: 39328262 Free PMC article. Review. - Recent advancements in improving the efficacy and safety of chimeric antigen receptor (CAR)-T cell therapy for hepatocellular carcinoma.
Ren T, Huang Y. Ren T, et al. Naunyn Schmiedebergs Arch Pharmacol. 2024 Sep 24. doi: 10.1007/s00210-024-03443-7. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 39316087 Review. - Using the Jurkat reporter T cell line for evaluating the functionality of novel chimeric antigen receptors.
Jahan F, Koski J, Schenkwein D, Ylä-Herttuala S, Göös H, Huuskonen S, Varjosalo M, Maliniemi P, Leitner J, Steinberger P, Bühring HJ, Vettenranta K, Korhonen M. Jahan F, et al. Front Mol Med. 2023 Feb 22;3:1070384. doi: 10.3389/fmmed.2023.1070384. eCollection 2023. Front Mol Med. 2023. PMID: 39086686 Free PMC article. - Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma.
Rujirachaivej P, Siriboonpiputtana T, Luangwattananun P, Yuti P, Wutti-In Y, Choomee K, Sujjitjoon J, Chareonsirisuthigul T, Rerkamnuaychoke B, Junking M, Yenchitsomanus PT. Rujirachaivej P, et al. Clin Exp Med. 2024 Apr 29;24(1):90. doi: 10.1007/s10238-024-01347-7. Clin Exp Med. 2024. PMID: 38683232 Free PMC article. - GD2-targeting therapy: a comparative analysis of approaches and promising directions.
Philippova J, Shevchenko J, Sennikov S. Philippova J, et al. Front Immunol. 2024 Mar 15;15:1371345. doi: 10.3389/fimmu.2024.1371345. eCollection 2024. Front Immunol. 2024. PMID: 38558810 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous